ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular diseases,
today announced that Robert E. Conway, has been elected Chairman of the
Company’s Board of Directors. He serves on the Audit and Compensation
Committees of the Board of Directors.
Mr. Conway has over 30 years of executive leadership experience in the
pharmaceutical and biotechnology industries. Mr. Conway served as the
Chief Executive Officer and member of the Board of Directors of Array
BioPharma from 1999 to 2012. Array is a biopharmaceutical company
focused on the discovery, development and commercialization of targeted
small molecule drugs to treat patients afflicted with cancer and
inflammatory diseases. Prior to joining Array, Mr. Conway was the Chief
Operating Officer and Executive Vice President of Hill Top Research,
Inc., a clinical research services company, from 1996 to 1999. He also
held various executive positions for Corning Inc. including Corporate
Vice President and General Manager of Corning Hazleton, Inc., a contract
research organization. Mr. Conway serves as the Chairman of Wall Family
Enterprise, a leading library and education supplies company. He is on
the Board of Directors of eResearch Technology, Inc. In addition, Mr.
Conway is a member of the Strategic Advisory Committee of Genstar
Capital, LLC.
“Bob’s experience and leadership are a tremendous asset to ARCA,” said
Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA.
“With his significant experience in leading both drug development
efforts and companies in the biopharmaceutical sector, Bob’s input and
guidance be valuable to the ARCA Board as we continue the development of
Gencaro and look to deliver value to our stockholders.”
“I am honored to accept this role with the ARCA Board of Directors,”
said Mr. Conway. “This is an exciting time for the organization with the
GENETIC-AF trial under way. We believe there is an unmet medical need
for new atrial fibrillation treatments. The GENETIC-AF trial, conducted
with the collaboration of Medtronic, will hopefully provide important
new data for the atrial fibrillation community.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
GencaroTM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the GENETIC-AF trial. For more
information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of
the safe harbor provided by the Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to, statements
regarding, potential timing for patient enrollment in the GENETIC-AF
trial, the sufficiency of the Company’s capital to support its
operations, the potential for genetic variations to predict individual
patient response to Gencaro, Gencaro’s potential to treat atrial
fibrillation, future treatment options for patients with atrial
fibrillation, and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management's current expectations and involve
risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as a
result of many factors, including, without limitation, the risks and
uncertainties associated with: the Company's financial resources and
whether they will be sufficient to meet the Company's business
objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process; and,
the impact of competitive products and technological changes. These and
other factors are identified and described in more detail in ARCA’s
filings with the SEC, including without limitation the Company’s annual
report on Form 10-K for the year ended December 31, 2013, and subsequent
filings. The Company disclaims any intent or obligation to update these
forward-looking statements.
Copyright Business Wire 2014